Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-10, Stock:JNJ, The news for the past five days is as follows:
2018-01-03: NEWS1: Why This Is the Perfect Level to Buy Celgene Corporation Stock.NEWS2: The Vanguard Health Care ETF Is a Strong Buy After Its Powerful Rally.NEWS3: Dr. Paul Janssen Award for Biomedical Research Issues 2018 Call for Nominations to Celebrate Champions of Science.NEWS4: FDA issues recall on J&J heart device.NEWS5: Why This Is the Perfect Level to Buy Celgene Corporation Stock.NEWS6: Bank of America Corp Is Red Hot, But Don’t Get Burnt!.NEWS7: Can Merck Regain its Mojo in 2018 After an Unimpressive '17?.NEWS8: J&J"s Ethicon Wants to Expedite Appeal After Jurisdiction Dispute Loss in Pennsylvania.NEWS9: The Vanguard Health Care ETF Is a Strong Buy After Its Powerful Rally.NEWS10: Johnson & Johnson’s Growth Rates and Trends in 3Q17.NEWS11: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for January 04, 2018.NEWS12: Johnson & Johnson’s Quarterly Revenue Trend in 3Q17.NEWS13: Johnson & Johnson’s Valuation in December 2017.
2018-01-04: NEWS1: How Will Pfizer's Oncology Segment Shape Up In The Coming Years?.NEWS2: Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?.NEWS3: Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?.NEWS4: Johnson & Johnson’s Consumer Business Performance in 3Q17.NEWS5: Johnson & Johnson’s Pharmaceutical Business Performance in 3Q17.NEWS6: Why 2018 is a make-or-break year for pharma.NEWS7: Healthcare Stocks: Year In Review; Your Growth Prescriptions For 2018.NEWS8: Johnson & Johnson’s Business Segments in 3Q17.
2018-01-05: NEWS1: A Look at Pfizer’s Valuation.NEWS2: A Look At Johnson & Johnson's Medical Devices Segment.NEWS3: The Slow Push Upward Continues for Johnson & Johnson Stock.NEWS4: Will J&J (JNJ) Continue to Tread Growth Path This Year?.NEWS5: Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod.NEWS6: Johnson & Johnson changes hiring plan for regional HQ in Lake Nona.NEWS7: How Did Bausch + Lomb’s Top Products Perform in 3Q17?.NEWS8: Analysts’ Estimates for Johnson & Johnson.NEWS9: Celsion&apos;s Phase I/II Cancer Study Initiation Gets FDA Nod.NEWS10: Will J&J (JNJ) Continue to Tread Growth Path This Year?.NEWS11: To catch Apple, Fitbit invests in a start-up making tiny device to track blood sugar for diabetics.NEWS12: How Valeant Subsidiary Bausch + Lomb Performed in 3Q17.NEWS13: How the Health Care Sector Performed in 2017.NEWS14: Johnson & Johnson’s Profit Margins in 3Q17.NEWS15: The Slow Push Upward Continues for Johnson & Johnson Stock.NEWS16: Johnson & Johnson’s Medical Devices Business Performance in 3Q17.
2018-01-08: NEWS1: Novo Nordisk Makes $3.1 Billion Takeover Offer For Ablynx.NEWS2: Here's Why Insulet Corporation Jumped Today.NEWS3: 5 Big Trends in Jobs for 2018.NEWS4: Here&apos;s Why Insulet Corporation Jumped Today.NEWS5: 5 Big Trends in Jobs for 2018.NEWS6: 4 Tailwinds Driving Raymond James' Insulet Bull Case.NEWS7: Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs.NEWS8: IVV, JPM, JNJ, XOM: Large Inflows Detected at ETF.NEWS9: Celgene deal could be the first of many for biopharma as new tax law frees up cash.NEWS10: Alzheimer's takes Another Hit as Pfizer Ends Research in this Area.NEWS11: Pfizer to Stall R&D for Alzheimer&apos;s/Parkinson&apos;s, Cut Jobs.NEWS12: Alzheimer&apos;s takes Another Hit as Pfizer Ends Research in this Area.NEWS13: How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?.NEWS14: Analysts’ Recommendations for JNJ in December 2017.
2018-01-09: NEWS1: 3 Dividend Stocks That Are Perfect for Retirement.NEWS2: U.S. Stocks Continue to Make History.NEWS3: Close Update: Stocks Rally To Record Highs as Bonds Limp to the Close.NEWS4: Judge urges action on '100 percent manmade' opioid crisis.NEWS5: Markets Right Now: S&P 500 index marks its 6th straight gain.NEWS6: AbbVie’s Venclexta for Chronic Lymphocytic Leukemia.NEWS7: Dow Leads Rally As These 2 Blue Chips Power To Highs.NEWS8: Noteworthy Tuesday Option Activity: AGN, JNJ, HON.NEWS9: AbbVie Expects Peak Sales of $7 Billion for Imbruvica.NEWS10: This Top Growth Name Is Breaking Out; 2 Other Stocks Follow Suit.NEWS11: Stock Indexes Hit New Highs; Why J&J Is Hot.NEWS12: Dow Movers: NKE, JNJ.NEWS13: Geron Corporation's 13% Drop in 2017, Explained.NEWS14: Stock Indexes Hit New Highs; Why J&J Is Hot.NEWS15: Geron Corporation&apos;s 13% Drop in 2017, Explained.NEWS16: 7 Best Healthcare ETFs for 2018.NEWS17: Johnson & Johnson CEO: We should all be acting like Amazo....NEWS18: 2018 J.P. Morgan Healthcare Conference Roundup.NEWS19: Johnson & Johnson Wants to Create a Crisis -- and That&apos;s Great for Investors.NEWS20: Despite Setbacks, Drugmakers Have Plans to Fight Alzheimer’s.NEWS21: Biotech and pharma firms like the US tax law — but not because of their new rates.NEWS22: Biotech and pharma firms like the US tax law — but not because of their new rates.NEWS23: Drug Industry Isn't Giving Up on Alzheimer's.

Answer: Decrease